# EarliTec Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/earlitec-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Decatur, US
- Website: www.earlitecdx.com
- Total disclosed funding: $27M
- Latest round: Series B (Mar 19, 2024)
- Investors on record: 3

## About

Based in Georgia, US, and founded in 2019, EarliTec Diagnostics, Inc., aka EarliTec Dx, is a digital health company focused on the development of novel diagnostic and therapeutic technologies for children with ASD (autism spectrum disorder). In March 2024, EarliTec Diagnostics, Inc. raised USD 21.5 in series B funding co-led by Nexus NeuroTech Ventures and Venture Investors. The series B funding values EarliTec Diagnostics, Inc. at USD 59.28 million post-money. As of March 2022, the company is being led by its CEO, Tom Ressemann.

EarliTec Diagnostics, Inc. develops and offers EarliPoint® Evaluation for Autism Spectrum Disorder, a diagnostic device that leverages the Dynamic Quantification of Social-Visual Engagement (DQSVE) concept to analyze and quantify the observational behavior (moment-by-moment looking behavior) of a child, in order to identify and determine the severity levels of ASD or other early childhood vulnerabilities. The company’s solution allows caregivers, parents, and healthcare professionals to make data-driven interventions at the right time, resulting in the improved health condition of children.

## Funding rounds

- Series B, Mar 19, 2024, $22M — Venture Investors, Nexus NeuroTech Ventures
- Series A, Feb 4, 2022, $5.5M — GRA Venture Fund

## Investors

- GRA Venture Fund (https://capitalatlas.ai/funds/gra-venture-fund) — Series A
- Venture Investors — Series B
- Nexus NeuroTech Ventures (https://capitalatlas.ai/funds/nexus-neurotech-ventures) — Series B